Answers are grounded in this paper and cite their sources.
AIMS: The phase 3 ECHO trial demonstrated superior progression-free survival (PFS) with acalabrutinib plus bendamustine-rituximab (BR) versus placebo plus BR in treatment-naive (TN) mantle cell lymphoma (MCL). This analysis characterizes the pharmacokinetic (PK) profile of acalabrutinib and ACP-5862 (active metabolite) when administered with BR and evaluates exposure-response (efficacy/safety) relationships based on ECHO data. METHODS: In ECHO, patients aged ≥65 years with TN MCL received BR plus acalabrutinib or placebo. Acalabrutinib (100 mg twice daily) or placebo was administered at study start until progressive disease or unacceptable toxicity. A pooled population PK analysis dataset included 975 patients for acalabrutinib and 580 patients for ACP-5862 from ECHO plus 10 clinical trials. Exposure-response analyses examined associations between exposure and PFS, best overall response (BOR), and adverse events (AEs) from ECHO. RESULTS: Population PK analysis showed that demographics (age, body weight, sex, ethnicity, race) and other intrinsic factors (mild or moderate renal impairment; mild or moderate hepatic impairment) had no meaningful effect on acalabrutinib/ACP-5862 exposure. No impact of co-administration with BR was observed on PK exposure. Exposure-efficacy analyses of ECHO data showed a flat relationship between acalabrutinib/ACP-5862 exposure and PFS and BOR. Exposure-safety analyses of ECHO data showed no clinically meaningful correlation between acalabrutinib/ACP-5862 exposure and selected safety outcomes (grade ≥3 AEs and events of clinical interest, AEs leading to dose modifications). CONCLUSION: This analysis supports a fixed 100 mg twice daily acalabrutinib dose, in combination with BR, as well-tolerated and efficacious in treatment of patients with TN MCL.
No takes yet. Share an insight, caveat, or question.
Olabode et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: